- Report
- March 2024
- 196 Pages
Global
From €3212EUR$3,374USD£2,746GBP
€3569EUR$3,749USD£3,051GBP
- Report
- August 2023
- 240 Pages
Global
From €1895EUR$1,990USD£1,619GBP
- Report
- March 2024
- 89 Pages
Global
From €5332EUR$5,600USD£4,557GBP
- Clinical Trials
- February 2024
- 180 Pages
Global
From €2856EUR$3,000USD£2,441GBP
- Report
- October 2023
- 180 Pages
Global
From €4665EUR$4,900USD£3,988GBP
- Report
- July 2023
- 223 Pages
Global
From €4284EUR$4,500USD£3,662GBP
- Report
- May 2023
- 167 Pages
Global
From €2380EUR$2,500USD£2,035GBP
- Report
- November 2023
- 630 Pages
Global
From €9045EUR$9,500USD£7,731GBP
- Report
- May 2023
- 200 Pages
Global
From €7141EUR$7,500USD£6,104GBP
- Report
- November 2023
- 180 Pages
Global
From €4665EUR$4,900USD£3,988GBP
- Report
- February 2024
- 110 Pages
Global
From €4070EUR$4,275USD£3,479GBP
€4522EUR$4,750USD£3,866GBP
- Report
- February 2024
- 200 Pages
Global
From €2371EUR$2,490USD£2,026GBP
- Report
- June 2021
- 132 Pages
Global
From €4569EUR$4,799USD£3,905GBP
- Report
- December 2022
- 153 Pages
Global
From €4998EUR$5,250USD£4,272GBP
- Report
- November 2018
- 161 Pages
Global
From €1309EUR$1,375USD£1,119GBP
€2618EUR$2,750USD£2,238GBP
- Report
- March 2022
- 175 Pages
Global
From €1895EUR$1,990USD£1,619GBP
- Clinical Trials
- February 2021
- 60 Pages
Global
From €1428EUR$1,500USD£1,221GBP
- Report
- January 2022
- 60 Pages
Global
From €3761EUR$3,950USD£3,215GBP
- Report
- January 2022
- 60 Pages
Global
From €3761EUR$3,950USD£3,215GBP
- Report
- January 2022
- 200 Pages
Global
From €7141EUR$7,500USD£6,104GBP
The Non Small Cell Lung Cancer Drug market is a subset of the larger Lung Cancer Drug market. Non Small Cell Lung Cancer (NSCLC) is the most common type of lung cancer, accounting for approximately 85% of all lung cancer cases. NSCLC is typically treated with chemotherapy, radiation, and targeted therapies. Targeted therapies are drugs that target specific molecules involved in the growth and spread of cancer cells. These drugs are designed to block the growth and spread of cancer cells while limiting damage to healthy cells.
The Non Small Cell Lung Cancer Drug market is highly competitive, with a number of companies offering various treatments. Companies such as AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Merck, and Pfizer are some of the major players in the market. Other companies such as Amgen, Boehringer Ingelheim, and Novartis are also active in the market. Show Less Read more